Article Text

PDF
Evaluation of the Metasin assay for intraoperative assessment of sentinel lymph node metastases in breast cancer
  1. G J Smith1,
  2. E Hodges2,
  3. H Markham3,
  4. S Zhang1,
  5. R I Cutress4
    1. 1Department of Molecular Pathology, University Hospital Southampton, Southampton, UK
    2. 2Department of Immunology & Molecular Pathology, University Hospital Southampton, Southampton, UK
    3. 3University Hospital Southampton, Cellular Pathology, Southampton, UK
    4. 4University of Southampton, Cancer Sciences, Faculty of Medicine and University Hospital Southampton, Southampton Breast Unit, Southampton, UK
    1. Correspondence to Dr R I Cutress, Cancer Research UK Clinical Centre, Somers Cancer Research Building, MP824, Southampton General Hospital, Southampton SO16 6YD, UK; R.I.Cutress{at}soton.ac.uk

    Abstract

    Aims Sentinel lymph node (SLN) biopsy is the preferred surgical technique for staging the axilla in clinically node-negative breast cancer. Accurate intraoperative staging allows for the immediate performance of an axillary clearance in node-positive patients. We assessed the Metasin assay for the intraoperative analysis of SLNs in a prospective evaluation of 250 consecutive patients undergoing intraoperative SLN analysis at the Breast Unit, University Hospital, Southampton, UK.

    Methods Metasin uses a quantitative reverse transcription PCR to detect two markers of metastasis: cytokeratin 19 (CK19) an epithelial marker and mammaglobin (MGB) a breast specific marker. Metasin results were compared with the results from routine paraffin block histopathology.

    Results Metasin was robust, with a failure rate of <1%, and demonstrated excellent accuracy and reproducibility. The average turnaround time for the Metasin assay was 42 min, the largest variable being the number of nodes assayed. A total of 533 SLNs were evaluated with 75 patients testing positive for MGB and/or CK19. Based on the analysis of individual SLNs, the overall concordance between Metasin and histology was 92.3% (sensitivity 88.7%, specificity 92.9%). When adjusted for tissue allocation bias, the concordance was 93.8% (sensitivity 89.8%, specificity 94.6%). In this evaluation, 57/250 patients (23%) proceeded to axillary clearance based on Metasin results and were considered spared a second operative procedure.

    Conclusions Metasin has proven to be an accurate, reproducible and reliable laboratory test. The analysis time is acceptable for intraoperative use, and in comparison to routine histology demonstrates acceptable concordance, sensitivity and specificity.

    • SENTINEL NODE
    • BREAST CANCER
    • MOLECULAR PATHOLOGY

    Statistics from Altmetric.com

    Footnotes

    • Handling editor Cheok Soon Lee

    • Collaborators The Molecular Pathology staff who performed the Metasin analysis: A Afonso, Dr SJ Doherty, Dr RH Ganderton, CV Lee and N Meakin. The breast surgeons: Mr DA Rew, Mr GT Royle, Miss TG Simoes and Miss CM Summerhayes. The breast pathologists: Dr V Bhargava, Dr AC Bateman, Dr H Roche, Dr JM Theaker and Dr C Tilley.

    • Contributors GJS, RIC, HM, SZ and EH all contributed to the writing, editing and proof reading of this manuscript. GJS and SZ validated and implemented the Metasin assay. HM was the lead pathologist and performed extended analysis of the lymph nodes. EH and RIC led respectively, the service and surgical implementation, of the intraoperative assay.

    • Funding The League of Friends, University Hospital Southampton provided funding to purchase the thermal cycler and other equipment hardware costs to implement the Metasin assay.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.